Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Senzime AB ( (SE:SEZI) ) has provided an update.
Senzime AB announced that a major university hospital system in California has standardized on its TetraGraph system for neuromuscular monitoring, with an initial order of 35 systems to be used in operating rooms for over 10,000 surgeries annually. This strategic win enhances Senzime’s market position in the US, as hospitals seek to comply with guidelines and improve patient safety, while the TetraGraph system’s scalable business model continues to drive growth in a large, underpenetrated market.
The most recent analyst rating on (SE:SEZI) stock is a Hold with a SEK6.50 price target. To see the full list of analyst forecasts on Senzime AB stock, see the SE:SEZI Stock Forecast page.
More about Senzime AB
Senzime is a leading medical device company established in 1999, specializing in precision-based monitoring systems that enhance perioperative patient safety and reduce costs. The company’s flagship product, the TetraGraph® system, is renowned for its accurate neuromuscular transmission monitoring during surgery and is widely used globally. Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market and the US OTCQX Market.
Average Trading Volume: 474,319
Technical Sentiment Signal: Sell
Current Market Cap: SEK966.9M
For a thorough assessment of SEZI stock, go to TipRanks’ Stock Analysis page.